Quick Answer
Yes, semaglutide (Ozempic, Wegovy) and other GLP-1 receptor agonists appear to reduce cravings for food, alcohol, nicotine, and other addictive substances. The effect is driven by GLP-1 receptors in the brain's dopamine reward circuits. Multiple large studies have confirmed the signal. GLP-1 drugs are not FDA-approved for addiction, but the evidence is strong enough that clinical trials are actively underway.
What Cravings Does Ozempic Reduce?
Food cravings
Central to the drug's mechanism. Reduces appetite and reward-driven eating, especially for ultra-processed foods.
Alcohol cravings
Large dataset analyses show 30–50% lower AUD rates in GLP-1 users. Multiple trials underway.
Nicotine cravings
User reports and animal studies consistent. Clinical trials for smoking cessation underway.
Opioid cravings
Included in multi-substance dataset analyses showing reduced OUD rates in GLP-1 users.
Stimulant cravings
Reduced stimulant use disorder rates in GLP-1 users in large studies.
Gambling urges
Case reports and mechanism-based reasoning suggest possible effect on compulsive behaviors.
Does Ozempic reduce drug and alcohol cravings?
Emerging evidence suggests yes, semaglutide (Ozempic/Wegovy) appears to reduce cravings for alcohol, nicotine, opioids, and potentially other addictive substances. Mechanism: GLP-1 receptors are expressed in the mesolimbic dopamine system (the brain's reward pathway). GLP-1 agonists appear to blunt dopamine release in response to addictive stimuli, reducing the rewarding value of substances. Animal studies show dramatically reduced alcohol and drug consumption. Human evidence: observational data and clinical surveys of patients on semaglutide for diabetes or obesity report reduced alcohol consumption and cravings for multiple substances. Clinical trials are underway (NCT05520775 for alcohol use disorder). This is an exciting area of addiction medicine.
What is the science behind GLP-1 drugs reducing cravings?
GLP-1 (glucagon-like peptide-1) receptors are expressed throughout the brain's reward circuitry, including the ventral tegmental area, nucleus accumbens, and prefrontal cortex, the core of the dopamine reward system. GLP-1 agonists (semaglutide, liraglutide) appear to modulate dopamine signaling in response to rewarding stimuli: animal studies show reduced dopamine release and reduced consumption of alcohol, cocaine, opioids, and high-fat food. The 'craving reduction' mechanism may involve dampening the anticipatory dopamine response to addictive cues. This is a pharmacologically plausible mechanism, GLP-1 receptors in the reward system have been a research target for decades. Current clinical evidence in humans is preliminary but consistent with the animal model.
Can Ozempic help with alcohol use disorder?
Evidence for semaglutide in alcohol use disorder: preclinical data is compelling, rodents treated with semaglutide show dramatically reduced alcohol consumption and craving-like behavior. Human evidence: multiple observational reports of patients on semaglutide (prescribed for obesity or diabetes) spontaneously reducing alcohol consumption. A randomized controlled trial (NCT05520775) is ongoing. Observational analysis of large health records (2024) showed patients on GLP-1 agonists had lower rates of alcohol use disorder diagnosis vs. matched controls. Not yet FDA-approved for alcohol use disorder, current standard of care remains naltrexone (the most evidence-backed medication for AUD), acamprosate, and disulfiram. Semaglutide for AUD is promising but experimental.
Has Ozempic been tested for addiction treatment?
Ozempic/semaglutide addiction research status (as of 2025): multiple clinical trials are underway: alcohol use disorder (NCT05520775, Phase 2 RCT), nicotine dependence, and cocaine use disorder trials are in progress. Observational data: analyses of large electronic health record databases show GLP-1 agonist users have lower rates of multiple substance use disorder diagnoses. Animal study evidence: robust, GLP-1 agonism reduces consumption of alcohol, cocaine, opioids, and high-calorie food in rodent models. Liraglutide (a shorter-acting GLP-1 agonist) has shown craving and consumption reduction in human pilot studies. The field is moving quickly, clinical trials expected to report results within the next 1–3 years.
Does Ozempic reduce food cravings the same way it reduces drug cravings?
Yes, the same mechanism explains both food craving reduction and drug craving reduction. GLP-1 receptors in the hypothalamus regulate appetite and satiety (the mechanism behind Ozempic's weight loss effect). GLP-1 receptors in the mesolimbic dopamine system (the reward pathway) modulate the rewarding value of all dopamine-activating stimuli, including food, drugs, alcohol, and potentially other compulsive behaviors. Semaglutide appears to dampen reward signal across categories, not specifically for food. Patients on Ozempic report reduced craving not just for food but for alcohol, cigarettes, gambling, shopping, and other dopamine-activating behaviors. This suggests GLP-1 agonists may broadly modulate the reward system, with implications far beyond weight loss.
What do patients say about Ozempic reducing cravings?
Patient-reported craving reduction on Ozempic/semaglutide: widespread anecdotal and survey data from people prescribed semaglutide for obesity or diabetes report: reduced desire for alcohol (many describe spontaneously drinking less or stopping entirely), reduced nicotine cravings, reduced urges for high-sugar and high-fat foods, and some reports of reduced urges for gambling and compulsive shopping. These reports began accumulating in 2022–2023 as semaglutide prescriptions increased dramatically. A 2023 survey of GLP-1 users by KFF found significant proportions reporting reduced alcohol and nicotine cravings. These self-reports are consistent with the proposed mechanism and the animal evidence, but are not controlled trial data, individual variation is significant.
Can Ozempic help with nicotine addiction?
Evidence for semaglutide in nicotine addiction: preclinical data shows GLP-1 agonists reduce nicotine self-administration and withdrawal in rodents. Human evidence: survey and observational data from semaglutide users report reduced cigarette cravings and spontaneous smoking reduction. A clinical trial specifically examining semaglutide for nicotine cessation has been initiated. Current FDA-approved options for nicotine cessation (varenicline, bupropion, NRT) remain the standard of care. They are proven. Semaglutide for nicotine cessation is experimental but mechanistically plausible. People currently prescribed semaglutide who also smoke may notice reduced cravings, discussing this with their prescriber and capitalizing on the window with NRT or varenicline could be effective.
What are the side effects of Ozempic relevant to addiction treatment?
Semaglutide side effects relevant to addiction treatment: GI effects (nausea, vomiting, diarrhea, constipation), common, particularly at dose initiation, usually improve over weeks. These GI effects may independently reduce alcohol consumption (nausea after drinking is heightened on semaglutide). Reduced appetite (intended effect for weight loss, may affect nutritional adequacy during early recovery when nutrition is already compromised). Pancreatitis (rare but serious, caution in people with history of pancreatitis). Cost and access: semaglutide is expensive ($800–$1,200/month out-of-pocket), may not be covered by insurance for addiction treatment (currently only FDA-approved for obesity and diabetes). Requires weekly injection. These factors limit current accessibility for addiction applications.
Is Ozempic FDA-approved for addiction treatment?
As of 2025, semaglutide (Ozempic, Wegovy) is NOT FDA-approved for any addiction or substance use disorder indication. FDA approvals: Type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in obesity (2024). For addiction: multiple clinical trials are in progress, full RCT data is not yet available, FDA approval for addiction indications would require Phase 3 trial completion and FDA review. Off-label use: physicians can prescribe semaglutide off-label, and some addiction medicine physicians are beginning to consider it for patients with co-occurring obesity and SUD. Standard FDA-approved addiction treatments (naltrexone, buprenorphine, methadone, varenicline) remain the established standard of care.
How does Ozempic compare to naltrexone for alcohol cravings?
Semaglutide vs. naltrexone for alcohol cravings: naltrexone is FDA-approved for alcohol use disorder with decades of RCT evidence. It blocks opioid receptors (reducing the rewarding effect of alcohol and reducing cravings), has a well-established safety profile, and is generic and affordable ($30–$100/month). Semaglutide: promising preclinical and observational data, no completed RCT for AUD yet, expensive ($800+/month), approved for other indications. Current recommendation: naltrexone (or acamprosate) remains the evidence-based standard for alcohol use disorder pharmacotherapy. Semaglutide is experimental for this indication. For a patient already on semaglutide for obesity/diabetes who also has AUD: adding naltrexone or using the semaglutide-driven craving reduction as an entry point to treatment is worth discussing with a prescriber.
What GLP-1 drugs besides Ozempic may reduce cravings?
GLP-1 drugs with addiction research: liraglutide (Victoza, Saxenda, shorter-acting GLP-1 agonist) has the most human data for addiction, a small RCT showed reduced alcohol cravings and consumption in alcohol-dependent adults. Semaglutide (Ozempic, Wegovy, longer-acting, once-weekly) has the most current interest due to its high potency and wide availability. Tirzepatide (Mounjaro, Zepbound, dual GLP-1/GIP agonist) is even more potent for weight loss, its addiction-relevant effects are less studied but mechanistically plausible. Exenatide (Bydureon, Byetta) has preclinical data for addiction. The entire GLP-1 receptor agonist class likely shares the craving-reduction mechanism, semaglutide and liraglutide are the most clinically relevant based on current evidence.
Can Ozempic help with opioid cravings?
Semaglutide and opioid use disorder: preclinical data shows GLP-1 agonism reduces opioid self-administration and withdrawal behavior in rodent models. Human evidence is very limited, primarily case reports and observational data. The standard of care for opioid use disorder remains buprenorphine (Suboxone) and methadone, medications with extensive RCT evidence showing dramatic reduction in overdose deaths and relapse. Naltrexone (extended-release injection, Vivitrol) is also FDA-approved. Semaglutide for OUD is speculative at this stage. For the current opioid epidemic: the established medications (buprenorphine, methadone) should be the first-line treatment. Semaglutide as an adjunct in patients already on MAT is a possible future research direction.
What is the current state of research on GLP-1 drugs for addiction?
GLP-1 addiction research landscape (2025): multiple Phase 2 trials are underway (alcohol, nicotine, cocaine use disorders). Observational database studies have shown associations between GLP-1 use and lower rates of multiple SUD diagnoses. Liraglutide has the most completed human trial data (small RCTs showing reduced alcohol and nicotine use). Semaglutide trials are the most anticipated, given its potency and the scale of current prescribing, data will be informative. Key unknowns: optimal dosing for addiction indications (may differ from weight loss dosing), duration of effect, which specific disorders and populations respond best, and whether the effect is maintained long-term. The next 2–3 years will be defining for this research area. Follow progress at clinicaltrials.gov.
How might I access semaglutide for addiction if I'm interested?
Accessing semaglutide for addiction (as of 2025): semaglutide is not FDA-approved for addiction, prescribing for this indication would be off-label. Off-label prescribing is legal and common in medicine (the prescriber takes responsibility for the decision). For access: discuss with an addiction medicine physician or psychiatrist familiar with the research, if you have a co-occurring obesity or type 2 diabetes diagnosis, semaglutide may be on-label for that condition and could address addiction as a secondary benefit, insurance coverage for addiction off-label use is currently unlikely. Current recommendation: for most people, FDA-approved addiction treatments (naltrexone, buprenorphine, varenicline) should be first-line. They are proven, available, and often covered by insurance. Semaglutide is a promising complement, not yet a replacement.
The "Food Noise" Phenomenon, and Why It Applies to All Cravings
Semaglutide users frequently describe a phenomenon they call "food noise" going quiet, the constant background preoccupation with food simply stopping. Where before they thought about food between meals, planned what they'd eat next, or felt pulled toward certain foods, on the drug those thoughts largely disappear.
The same "noise" appears to go quiet for alcohol and other substances in people who were craving-driven users. Users describe no longer thinking about their next drink, losing interest in situations they previously associated with using, and feeling like the pull had been turned down to near-zero.
This is neurologically coherent: the same dopamine circuits that generate "food noise" generate "drug noise." If GLP-1 receptor activation in reward circuits quiets one, it quiets both.
The Mechanism: Dopamine Reward Circuits
GLP-1 receptors are found in the gut, pancreas, and, critically, in the brain. Specifically in the ventral tegmental area (VTA), the nucleus accumbens, and the prefrontal cortex: the core of the mesolimbic dopamine system that drives craving, reward, and compulsive behavior in addiction.
When semaglutide activates these receptors, it appears to modulate dopamine signaling in response to reward cues. The result is a reduction in anticipatory craving, the "wanting" that precedes use, without blocking pleasure from other sources. This is a different mechanism from naltrexone (which blocks opioid receptors) but targets the same ultimate pathway.
What the Evidence Actually Shows
The strongest evidence comes from large retrospective analyses of electronic health records. A 2024 Nature Communications study of 227,000+ patients found GLP-1 users had significantly lower rates of alcohol, opioid, stimulant, and cannabis use disorders compared to matched controls on other diabetes medications, ruling out the obvious confound that GLP-1 users are just healthier to start with.
Animal studies have consistently shown GLP-1 agonists reduce self-administration of alcohol, cocaine, opioids, and nicotine. Phase 2 clinical trials in humans for alcohol use disorder have produced promising preliminary results. Phase 3 trials are needed for regulatory approval, but the signal is robust.
Important Caveats
- Not FDA-approved for addiction. Semaglutide is approved for diabetes and obesity. Using it off-label for addiction requires a physician's judgment and isn't standard practice.
- The effect stops when the drug stops. Craving reduction is tied to ongoing medication use. Without behavioral changes during the medication period, gains may not persist after stopping.
- It's not a replacement for treatment. Medication reduces craving intensity. It doesn't address the psychological, social, and behavioral dimensions of addiction. Behavioral support remains essential.
- Side effects are significant. Nausea, vomiting, and GI distress are common, especially early on. These should be discussed with a physician before use.
Work on the behavioral side in parallel
Whether medication is part of your plan or not, building the daily habits of recovery matters. Forge tracks your streak and helps you manage cravings with evidence-based tools.
Download Forge FreeFrequently Asked Questions
Does Ozempic reduce cravings?
Yes, for food, alcohol, nicotine, and other substances. The effect is driven by GLP-1 receptors in the brain's dopamine reward circuits dampening anticipatory craving.
What cravings does Ozempic reduce most?
Food cravings most clearly (central to its mechanism). Alcohol cravings have the strongest evidence among substances. Nicotine, opioids, and stimulants have emerging evidence.
How quickly does Ozempic reduce cravings?
Many people notice reduced cravings within 1–4 weeks of starting, tracking with blood levels rising as doses increase.
Do cravings come back when you stop Ozempic?
Yes, the craving reduction is tied to ongoing use. Food cravings typically return within weeks to months of stopping.
Is Ozempic approved for addiction?
No, it's approved for type 2 diabetes and obesity only. Clinical trials for addiction indications are underway.
Should I use Ozempic instead of established addiction treatment?
No, use established FDA-approved treatments first. Ozempic is not a replacement for proven addiction care.
Related: Ozempic and Alcohol · Naltrexone for Alcohol · How to Deal with Cravings · Dopamine and Addiction